Analysts Set Omnicell, Inc. (NASDAQ:OMCL) Target Price at $59.86

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $59.8571.

Several equities analysts have weighed in on the company. Wells Fargo & Company raised their price target on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Benchmark reissued a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. UBS Group set a $60.00 price target on Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. Craig Hallum reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research report on Wednesday, April 29th. Finally, Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th.

Insiders Place Their Bets

In other news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the sale, the executive vice president owned 154,785 shares of the company’s stock, valued at $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This represents a 4.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 15,520 shares of company stock valued at $607,610. Company insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its position in shares of Omnicell by 31.3% in the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after purchasing an additional 138,537 shares during the period. California State Teachers Retirement System grew its position in shares of Omnicell by 14.2% in the first quarter. California State Teachers Retirement System now owns 50,323 shares of the company’s stock valued at $1,680,000 after purchasing an additional 6,273 shares during the period. Empowered Funds LLC grew its position in shares of Omnicell by 4,229.9% in the first quarter. Empowered Funds LLC now owns 262,043 shares of the company’s stock valued at $8,747,000 after purchasing an additional 255,991 shares during the period. Quantinno Capital Management LP grew its position in shares of Omnicell by 390.2% in the first quarter. Quantinno Capital Management LP now owns 57,560 shares of the company’s stock valued at $1,921,000 after purchasing an additional 45,817 shares during the period. Finally, First Light Asset Management LLC purchased a new stake in Omnicell during the first quarter valued at about $16,351,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Omnicell stock opened at $37.82 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. The stock has a fifty day moving average of $40.36 and a two-hundred day moving average of $41.50. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 85.96, a PEG ratio of 0.99 and a beta of 0.97. Omnicell has a fifty-two week low of $26.84 and a fifty-two week high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The company had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.Omnicell’s revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, analysts anticipate that Omnicell will post 1.31 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.